v3.22.2.2
Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details) - USD ($)
 12 Months Ended
Nov. 22, 2021
Oct. 03, 2018
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Deferred revenue     $ 74,099,000 $ 111,055,000  
Revenue     243,231,000 $ 138,287,000 $ 87,992,000
Collaboration and License agreements          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Initial transaction price   $ 252,700,000      
GSK | Collaboration and License agreements          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Milestone payment $ 120,000,000        
Milestone payment receivable at start of phase two 30,000,000        
Milestone payment receivable upon achievement of phase two and first patient dosed in phase three 100,000,000        
Initial transaction price 120,000,000        
Contract assets     4,800,000    
Deferred revenue     0    
Revenue     4,800,000    
GSK | Collaboration and License agreements | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Commercial milestone payments at first commercial sale 190,000,000        
Sales-related milestone payments $ 590,000,000        
GSK | A R O H S D Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Contract assets     0    
Deferred revenue     $ 0